We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Stryker (SYK) Down 2.8% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Stryker (SYK - Free Report) . Shares have lost about 2.8% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Stryker due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Stryker Earnings and Revenues Miss Estimates in Q1
Stryker Corporation reported first-quarter 2021 adjusted earnings per share of $1.93, which missed the Zacks Consensus Estimate of $1.98 by 2.5%. However, the bottom line improved 4.9% year over year.
Revenue Details
The Michigan-based medical device company reported revenues of $3.95 billion, which lagged the Zacks Consensus Estimate by 0.2%. Nonetheless, the top line increased 10.2% on a year-over-year basis and 8% at constant currency (cc).
Revenues by Geography
Revenues in United States were $2.78 billion, up 5.3% year over year. International sales were up 23.7% to $1.17 billion.
Segmental Analysis
Orthopaedics: In the quarter under review, revenues in the segment totaled $1.48 billion, up 21.4% year over year. The segment’s revenues rose 18.7% at cc. The upside can be attributed to strong performance at the Trauma and Extremities and Other sub segments, and growth in Mako.
MedSurg: This segment reported sales of $1.62 billion, which remained flat on year-over-year basis. Sales at the segment declined 1.6% at cc. Per management, the segment decreased 1.6% organically in the reported quarter.
Neurotechnology and Spine: Sales in the segment amounted to $848 million, up 14% year over year and 11.3% at cc. Organically, the segment witnessed a rise of 11.3%. Per management, the upside can be attributed to double-digit growth in the company’s Interventional spine, neurosurgical and ENT businesses. Also, growth (27%) in Stryker’s neurovascular business contributed to the improvement.
Margins
In the first quarter, adjusted gross profit totaled $2.59 billion, up 10.5% from the year-ago quarter. Adjusted gross margin was 65.4%, up 10 basis points (bps).
Adjusted operating income amounted to $928 million, up 7.7% from the prior-year quarter. Adjusted operating margin was 23.5%, down 50 bps.
Financial Update
The company exited the first quarter with cash and cash equivalents of $2.24 billion, compared with $2.94 billion in the prior quarter.
Net cash provided by operating activities in the first quarter were $452 million, reflecting a decrease of 23.5% from the year-ago period.
2021 Outlook
The company will continue to track and evaluate the impact of the COVID-19 pandemic on its operations and financial results. With the ongoing recovery from the pandemic, Stryker anticipates organic net sales growth between 8% and 10% from that of 2019.
Adjusted EPS is projected in the band of $9.05 to $9.30 (which includes impact of the buyout of Wright Medical for the full year). The Zacks Consensus Estimate for the same is pegged at $9.05.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
VGM Scores
Currently, Stryker has a nice Growth Score of B, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Stryker has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Stryker (SYK) Down 2.8% Since Last Earnings Report?
A month has gone by since the last earnings report for Stryker (SYK - Free Report) . Shares have lost about 2.8% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Stryker due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Stryker Earnings and Revenues Miss Estimates in Q1
Stryker Corporation reported first-quarter 2021 adjusted earnings per share of $1.93, which missed the Zacks Consensus Estimate of $1.98 by 2.5%. However, the bottom line improved 4.9% year over year.
Revenue Details
The Michigan-based medical device company reported revenues of $3.95 billion, which lagged the Zacks Consensus Estimate by 0.2%. Nonetheless, the top line increased 10.2% on a year-over-year basis and 8% at constant currency (cc).
Revenues by Geography
Revenues in United States were $2.78 billion, up 5.3% year over year. International sales were up 23.7% to $1.17 billion.
Segmental Analysis
Orthopaedics: In the quarter under review, revenues in the segment totaled $1.48 billion, up 21.4% year over year. The segment’s revenues rose 18.7% at cc. The upside can be attributed to strong performance at the Trauma and Extremities and Other sub segments, and growth in Mako.
MedSurg: This segment reported sales of $1.62 billion, which remained flat on year-over-year basis. Sales at the segment declined 1.6% at cc. Per management, the segment decreased 1.6% organically in the reported quarter.
Neurotechnology and Spine: Sales in the segment amounted to $848 million, up 14% year over year and 11.3% at cc. Organically, the segment witnessed a rise of 11.3%. Per management, the upside can be attributed to double-digit growth in the company’s Interventional spine, neurosurgical and ENT businesses. Also, growth (27%) in Stryker’s neurovascular business contributed to the improvement.
Margins
In the first quarter, adjusted gross profit totaled $2.59 billion, up 10.5% from the year-ago quarter. Adjusted gross margin was 65.4%, up 10 basis points (bps).
Adjusted operating income amounted to $928 million, up 7.7% from the prior-year quarter. Adjusted operating margin was 23.5%, down 50 bps.
Financial Update
The company exited the first quarter with cash and cash equivalents of $2.24 billion, compared with $2.94 billion in the prior quarter.
Net cash provided by operating activities in the first quarter were $452 million, reflecting a decrease of 23.5% from the year-ago period.
2021 Outlook
The company will continue to track and evaluate the impact of the COVID-19 pandemic on its operations and financial results. With the ongoing recovery from the pandemic, Stryker anticipates organic net sales growth between 8% and 10% from that of 2019.
Adjusted EPS is projected in the band of $9.05 to $9.30 (which includes impact of the buyout of Wright Medical for the full year). The Zacks Consensus Estimate for the same is pegged at $9.05.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
VGM Scores
Currently, Stryker has a nice Growth Score of B, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Stryker has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.